NCT02295865 is a Phase 2 clinical trial of JNJ-38518168 60 mg in Psoriasis, sponsored by Janssen Research & Development, LLC.

Who is sponsoring NCT02295865?

NCT02295865 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT02295865?

Interventions in NCT02295865: JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo.

Is NCT02295865 still recruiting?

NCT02295865 is currently completed. Last updated 7 July 2017.

Last reviewed 2017-07-07 · How we verify

NCT02295865

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

Completed Phase 2 Last updated 7 July 2017

What this trial tests

Phase 2 trial testing JNJ-38518168 60 mg in Psoriasis in 62 participants. Completed in 11 March 2016.

Timeline

17 November 2014

Primary endpoint
11 March 2016

11 March 2016

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	62
Start date	17 November 2014
Primary completion	11 March 2016
Estimated completion	11 March 2016
Sites	13 locations across United States, Poland

Drugs / interventions tested

JNJ-38518168 60 mg — full drug profile →
JNJ-38518168 30 mg — full drug profile →
JNJ-38518168 3 mg — full drug profile →
Placebo

Conditions studied

Psoriasis — all drugs for Psoriasis →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

18 and older, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-38518168 in participants with moderate to severe plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches).

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets.
Thangam EB, Jemima EA, Singh H, Baig MS, et al · · 2018 · cited 347× · PMID 30150993 · DOI 10.3389/fimmu.2018.01873
The histamine H4 receptor: from orphan to the clinic.
Thurmond RL. · · 2015 · cited 85× · PMID 25873897 · DOI 10.3389/fphar.2015.00065
The role of the histamine H<sub>4</sub> receptor in atopic dermatitis and psoriasis.
Schaper-Gerhardt K, Rossbach K, Nikolouli E, Werfel T, et al · · 2020 · cited 55× · PMID 30460986 · DOI 10.1111/bph.14550
New antihistamines - perspectives in the treatment of some allergic and inflammatory disorders.
Tatarkiewicz J, Rzodkiewicz P, Żochowska M, Staniszewska A, et al · · 2019 · cited 19× · PMID 30899308 · DOI 10.5114/aoms.2017.68534
Enigmatic Histamine Receptor H<sub>4</sub> for Potential Treatment of Multiple Inflammatory, Autoimmune, and Related Diseases.
Mehta P, Miszta P, Rzodkiewicz P, Michalak O, et al · · 2020 · cited 18× · PMID 32344736 · DOI 10.3390/life10040050
Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
Grekowitz E, Metz M, Altrichter S, Bauer A, et al · · 2024 · cited 4× · PMID 38308655 · DOI 10.1093/bjd/ljae038

Verify or expand the search:

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02295865 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 7 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02295865.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing